---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-003159"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:50:32.404560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass reports CTX-009 42% ORR in biliary tract cancers; to start U.S. Phase 2 in Q3 2022

## Summary
- CTX-009 + paclitaxel achieved 42% ORR (10 PRs) out of 24 patients with advanced biliary tract cancers.
- Clinical benefit rate 92% (22/24 patients had PR or stable disease); responses across all four BTC subtypes.
- Safety consistent with Phase 1: common AEs included hypertension (50%) and neutropenia (54.2%); manageable.
- Plans to initiate Stage 2 of Phase 2 study in the U.S. in Q3 2022, following Simon Two-Stage design criteria met.

## SEC filing metadata
- accession: 0001171843-22-003159
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184322003159/0001171843-22-003159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184322003159/f8k_050422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-003159
- JSON: https://secwatch.observer/filing/0001171843-22-003159.json
- Plain text: https://secwatch.observer/filing/0001171843-22-003159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.